|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLINICAL STUDY |
N Gulcelik, Department of Endocrinology and Metabolism, Hacettepe University Medical School, Ankara, 06100, Turkey
J Karakaya, Department of Biostatistics, Hacettepe University Medical school, Ankara, Turkey
A Gedik, Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey
A Usman, Department of Endocrinology and Metabolism, Hacettepe University Medical School, Ankara, Turkey
A Gurlek, Ankara, Turkey
Correspondence: Nese Ersoz Gulcelik, Email: nersoz{at}hacettepe.edu.tr
Abstract
Objective: Vaspin is a novel adipokine that has insulin sensitizing effects. The association between serum vaspin levels and diabetic complications is unknown. In this study, we aimed to evaluate serum vaspin levels as related to glycemic status and the presence of complications in a group of type 2 diabetic women.
Materials and Methods: We evaluated 37 type 2 diabetic female patients and 37 control female subjects who were matched for age and body mass index. Anthropometric measurements, insulin, hemoglobin A1c, C- reactive protein, and serum vaspin levels were measured in each participant. Furthermore, the patients were evaluated for diabetic neuropathy, retinopathy and, nephropathy.
Results: In diabetic patients, serum vaspin levels correlated positively with HbA1c and correlated negatively with insulin levels and HOMA. The patients with HbA1c levels
7% had lower levels of serum vaspin than patients with HbA1c levels >7% (0.11±0.06ng/ml vs. 0.20±0.09ng/ml, p<0.05). In patients with neuropathy, retinopathy and, nephropathy, serum vaspin levels were lower than in patients without neuropathy (0.10±0.07ng/ml vs. 0.17±0.09ng/ml, p=0.041), retinopathy (0.11±0.06ng/ml vs. 0.18±0.09ng/ml, p=0.019) and nephropathy (0.11±0.05ng/ml vs. 0.18±0.09ng/ml, p=0.02). Diabetic patients receiving metformin therapy had lower vaspin levels than patients not receiving metformin.
Conclusion: Diabetic women with good glycemic control have lower levels of vaspin than those with poor glycemic control. However, presence of microvascular complications is also associated with low vaspin levels. In order to use serum vaspin levels as a marker, evaluating patients for complications and medications interfering with serum vaspin levels seems appropriate.
This article has been cited by other articles:
![]() |
C. v. Loeffelholz, M. Mohlig, A. M Arafat, F. Isken, J. Spranger, K. Mai, H. S Randeva, A. F H Pfeiffer, and M. O Weickert Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans Eur. J. Endocrinol., March 1, 2010; 162(3): 507 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. González, J. E. Caminos, M. J. Vázquez, M. F. Garcés, L. A. Cepeda, A. Ángel, A. C. González, M. E. García-Rendueles, S. Sangiao-Alvarellos, M. López, et al. Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue J. Physiol., July 15, 2009; 587(14): 3741 - 3750. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |